Fig. 3From: High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcomeForrest plots summarizing multivariate analysis and relationship between analyzed variables and (a) survival and (b) likelihood to response to IL2Back to article page